Tracking lobular breast cancer with a blood test
Part of Cancer, Skin clinical trials.
This study is testing a new blood test that looks for cancer DNA to track how lobular breast cancer responds to treatment. It is for people whose cancer has spread and who have not yet started treatment for the spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have invasive lobular breast cancer that is hormone receptor-positive and HER2-negative.
- Your cancer has spread to other parts of the body (metastatic).
- You have not yet received any treatment for the metastatic cancer.
- You have a tumor sample available for genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well imaging scans and blood tests can show where invasive lobular breast cancer has spread in the body. It may help doctors better understand and monitor this type of cancer.
This study collects health information from adults with invasive lobular breast cancer that has spread (metastatic) to help researchers understand factors linked to survival. Joining may help build better knowledge for future treatments and care planning.
This trial tests a new imaging agent, [68Ga]Ga DOTA-5G, to see if it can better detect invasive lobular breast cancer that has spread to other parts of the body. It involves a PET/CT scan and may help doctors understand the extent of your cancer.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
This study uses a blood test and imaging to predict whether breast cancer has spread to underarm lymph nodes, helping guide surgery. It may reduce unnecessary lymph node removal.
Hear when a new Metastatic Invasive Lobular Carcinoma (mILC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.